Sign in

CIK 0001570562 · Accelerated filer

Evolus, Inc.

Sign in to watch
Ticker
EOLS
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
operating
EIN
461385614
Phone
(949) 284-4555
Business address
520 NEWPORT CENTER DRIVE, SUITE 1200, NEWPORT BEACH, CA, 92660
Former names
Evolus, Inc.
  1. 4 Open-market sale See Remarks sold 105,108 shares at $9.04 ($950,019)
  2. 4 Open-market sale See Remarks sold 3,119 shares at $4.75 ($14,815)
  3. 4 Planned sale See Remarks sold 13,669 shares at $4.75 ($64,929)
  4. 4 Planned sale See Remarks sold 116,720 shares at $4.89 ($570,562)
  5. 4 Planned sale See Remarks sold 29,996 shares at $4.89 ($146,629)
  6. 4 Grant or award Director acquired 45,559 shares (grant or award)
  7. 4 Grant or award Director acquired 45,559 shares (grant or award)
  8. 4 Grant or award Chief Financial Officer acquired 121,489 shares (grant or award)
  9. 4 Grant or award Director acquired 45,559 shares (grant or award)
  10. 4 Grant or award See Remarks acquired 313,212 shares (grant or award)
  11. 4 Grant or award Director acquired 45,559 shares (grant or award)
  12. 4 Grant or award See Remarks acquired 94,913 shares (grant or award)
  13. 4 Grant or award Director acquired 45,559 shares (grant or award)
  14. 4 Planned sale See Remarks sold 10,539 shares at $7.15 ($75,361)
  15. 4 Planned sale See Remarks sold 2,261 shares at $7.15 ($16,168)
  16. 4 Grant or award Chief Financial Officer acquired 104,603 shares (grant or award)
  17. 3 Insider Initial Statement of Ownership
  18. 4 Planned sale Chief Marketing Officer sold 5,722 shares at $7.51 ($42,972)
  19. 4 Open-market buy Director bought 30,000 shares at $6.82 ($204,486)
  20. 4 Open-market sale See Remarks sold 127,905 shares at an average $10.03 ($1,283,195)

Page 1 of 13 · 252 filings